Endocrine Abstracts

Objective: To determine if the response to one single dose of 0.5 mg cabergoline (CAB) can be used as predictor for choosing personalized therapy of hyperprolactinaemia. Although CAB is a selective, long half-life D2-receptor agonist some patients proved to be resistant with minimum to no response in serum prolactin and tumour shrinkage, even after a few months of treatment.Patients and methods: A dose of 0.5 mg CAB was administered orally to a number of...